QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NASDAQ:SHPG

Shire (SHPG) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$179.20
$179.20
50-Day Range
$179.20
$179.20
52-Week Range
$123.73
$182.47
Volume
N/A
Average Volume
2.21 million shs
Market Capitalization
$54.71 billion
P/E Ratio
11.83
Dividend Yield
0.19%
Price Target
N/A

SHPG stock logo

About Shire (NASDAQ:SHPG) Stock

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Receive SHPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shire and its competitors with MarketBeat's FREE daily newsletter.

SHPG Stock News Headlines

Shire Stock Hits New 52-Week High (SHPG)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Amanda Shires : Fresh Air - NPR
Amanda Shires - Take It Like A Man - Country Standard Time
See More Headlines


SHPG Company Calendar

Last Earnings
4/26/2018
Today
6/05/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SHPG
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$4.27 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$15.16 billion
Cash Flow
$22.71 per share
Book Value
$119.43 per share

Miscellaneous

Free Float
N/A
Market Cap
$54.71 billion
Optionable
Optionable
Beta
0.87

Key Executives

  • Dr. Flemming  Ornskov M.P.H.Dr. Flemming Ornskov M.P.H. (Age 60)
    MBA, M.D., MPH, CEO, MD & Exec. Director
  • Mr. Thomas J. W. Dittrich (Age 54)
    CFO & Director
  • Gisele Dion
    Chief Accounting Officer
  • Mr. Matthew Walker (Age 54)
    Head of Technical Operations
  • Dr. Andreas Busch Ph.D. (Age 55)
    Head of R&D and Chief Scientific Officer













SHPG Stock - Frequently Asked Questions

How were Shire's earnings last quarter?

Shire plc (NASDAQ:SHPG) issued its quarterly earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.58 by $0.28. The biopharmaceutical company earned $3.77 billion during the quarter. Shire had a trailing twelve-month return on equity of 12.70% and a net margin of 30.63%. The company's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the firm earned $3.63 EPS.

Is Shire a good dividend stock?

Shire (NASDAQ:SHPG) pays an annual dividend of $0.34 per share and currently has a dividend yield of 0.19%. The dividend payout ratio is 2.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SHPG will have a dividend payout ratio of 2.15% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for SHPG.

What other stocks do shareholders of Shire own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Walt Disney (DIS), Johnson & Johnson (JNJ), Pfizer (PFE), Starbucks (SBUX) and Exxon Mobil (XOM).

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

What is Shire's stock price today?

One share of SHPG stock can currently be purchased for approximately $179.20.

How much money does Shire make?

Shire (NASDAQ:SHPG) has a market capitalization of $54.71 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis.

How can I contact Shire?

Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The official website for the company is www.shire.com. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at rcoates@shire.com.

This page (NASDAQ:SHPG) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -